中国医疗集团(08225.HK):新型肺炎药迈可欣即将开展海外临床研究
中国医疗集团(08225.HK)公布,为回应国际抗击新冠病毒COVID-19市场紧急需求,与一家国际CRO公司Pharmadesk 签署了《迈可欣口服液生物等效性研究协议》,Pharmadesk公司已经成功地为全球客户进行了 500 多项符合国际规范市场法规要求的 BE 研究,没有一项研究被EMEA或美国FDA拒绝 。
迈可欣(利托那韦(Ritonavir)口服液)为公司关联企业万全万特制药(厦门)於今年2月获得独家复产批准的产品,利托那韦是抗病毒蛋白(酉每)抑制剂,洛匹那韦/利托那韦为国家卫健委针对新型肺炎的国家版诊疗方案推荐用药。
集团指,正与北京大学、厦门大学和海南大学的科学家共建世界级抗病毒药物的研究院。集团通过「研究型治疗 RWS-Therapy 模式」展开对COVID-19的後临床研究和治疗,与微医集团和妙手医生集团联手百名心理医疗专家和控烟专家,展开疫情後时代的精神心理健康的云端喜心诊所和护肺悦戒烟诊所驰援。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.